BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35551640)

  • 1. PIK3CA-related overgrowth with an uncommon phenotype: case report.
    Rotunno R; Diociaiuti A; Pisaneschi E; Carnevale C; Dentici M; El Hachem M
    Ital J Pediatr; 2022 May; 48(1):71. PubMed ID: 35551640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
    Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
    Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pitfalls in the diagnosis of segmental overgrowth syndromes: a child with the c.2740G > A mutation in PIK3CA gene.
    Maguolo A; Antoniazzi F; Spano A; Fiorini E; Gaudino R; Mauro M; Cantalupo G; Biban P; Maitz S; Cavarzere P
    Ital J Pediatr; 2018 Sep; 44(1):110. PubMed ID: 30231930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
    Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
    Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
    Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
    Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the
    Chen WL; Pao E; Owens J; Glass I; Pritchard C; Shirts BH; Lockwood C; Mirzaa GM
    Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline PTPN11 and somatic PIK3CA variant in a boy with megalencephaly-capillary malformation syndrome (MCAP)--pure coincidence?
    Döcker D; Schubach M; Menzel M; Spaich C; Gabriel HD; Zenker M; Bartholdi D; Biskup S
    Eur J Hum Genet; 2015 Mar; 23(3):409-12. PubMed ID: 24939587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations.
    Park HJ; Shin CH; Yoo WJ; Cho TJ; Kim MJ; Seong MW; Park SS; Lee JH; Sim NS; Ko JM
    Orphanet J Rare Dis; 2020 Aug; 15(1):205. PubMed ID: 32778138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
    de Kock L; Cuillerier A; Gillespie M; Couse M; Hartley T; Mears W; Bernier FP; Chudley AE; Frosk P; Nikkel SM; Innes AM; Lauzon J; Thomas M; Guerin A; Armour CM; Weksberg R; Scott JN; Watkins D; Harvey S; Cytrynbaum C; ; Kernohan KD; Boycott KM
    Am J Med Genet A; 2024 Mar; 194(3):e63466. PubMed ID: 37949664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebellar dysplasia related to PIK3CA mutation: a three-case series.
    Di Stasi M; Izzo G; Cattaneo E; Baraldini V; Doneda C; Righini A; Graziani D; Toto V; Parazzini C
    Neurogenetics; 2021 Mar; 22(1):27-32. PubMed ID: 32901329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
    Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
    Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
    Di Donato N; Rump A; Mirzaa GM; Alcantara D; Oliver A; Schrock E; Dobyns WB; O'Driscoll M
    Hum Mutat; 2016 Mar; 37(3):242-5. PubMed ID: 26593112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain Abnormalities in PIK3CA-Related Overgrowth Spectrum: Physician, Patient, and Caregiver Experiences.
    Dexheimer J; Mirzaa GM
    Adv Ther; 2022 Sep; 39(9):3871-3880. PubMed ID: 35857185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA vascular overgrowth syndromes: an update.
    Hughes M; Hao M; Luu M
    Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
    Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
    Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
    Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
    Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoinsulinaemic, hypoketotic hypoglycaemia due to mosaic genetic activation of PI3-kinase.
    Leiter SM; Parker VER; Welters A; Knox R; Rocha N; Clark G; Payne F; Lotta L; Harris J; Guerrero-Fernández J; González-Casado I; García-Miñaur S; Gordo G; Wareham N; Martínez-Glez V; Allison M; O'Rahilly S; Barroso I; Meissner T; Davies S; Hussain K; Temple K; Barreda-Bonis AC; Kummer S; Semple RK
    Eur J Endocrinol; 2017 Aug; 177(2):175-186. PubMed ID: 28566443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.